-$0.63 Earnings Per Share Expected for Immune Design Corp. (IMDZ) This Quarter
Analysts expect that Immune Design Corp. (NASDAQ:IMDZ) will announce ($0.63) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Immune Design Corp.’s earnings. The lowest EPS estimate is ($0.74) and the highest is ($0.49). Immune Design Corp. posted earnings per share of ($0.60) in the same quarter last year, which indicates a negative year-over-year growth rate of 5%. The company is scheduled to announce its next quarterly earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Immune Design Corp. will report full-year earnings of ($2.28) per share for the current financial year, with EPS estimates ranging from ($2.54) to ($1.93). For the next financial year, analysts expect that the firm will report earnings of ($2.24) per share, with EPS estimates ranging from ($2.43) to ($2.07). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Immune Design Corp..
Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. The business had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.50 million. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%.
A number of research analysts have recently issued reports on IMDZ shares. BidaskClub lowered Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. Royal Bank Of Canada initiated coverage on Immune Design Corp. in a research note on Thursday, September 14th. They set an “outperform” rating and a $20.00 price target for the company. ValuEngine raised Immune Design Corp. from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $18.00 price target on shares of Immune Design Corp. in a report on Wednesday, June 28th. Finally, Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp. in a research report on Tuesday, June 6th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $16.33.
Immune Design Corp. (IMDZ) traded up 0.93% during trading on Tuesday, hitting $10.80. 96,110 shares of the stock traded hands. The stock’s market cap is $276.69 million. The firm’s 50-day moving average is $9.75 and its 200-day moving average is $8.34. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $13.05.
WARNING: “-$0.63 Earnings Per Share Expected for Immune Design Corp. (IMDZ) This Quarter” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/03/0-63-earnings-per-share-expected-for-immune-design-corp-imdz-this-quarter.html.
In other Immune Design Corp. news, Director Lewis W. Coleman acquired 8,000 shares of the stock in a transaction on Friday, July 7th. The shares were bought at an average price of $9.27 per share, with a total value of $74,160.00. Following the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $370,800. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Leo Guthart acquired 10,000 shares of the stock in a transaction on Monday, September 18th. The stock was acquired at an average cost of $9.70 per share, for a total transaction of $97,000.00. The disclosure for this purchase can be found here. Insiders have purchased 40,000 shares of company stock valued at $369,760 over the last three months. 20.70% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its stake in shares of Immune Design Corp. by 170.0% during the 1st quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock worth $760,000 after buying an additional 70,351 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Immune Design Corp. by 2.1% in the second quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock valued at $19,281,000 after buying an additional 40,010 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Immune Design Corp. in the first quarter valued at approximately $183,000. Wells Fargo & Company MN grew its holdings in Immune Design Corp. by 46.5% during the first quarter. Wells Fargo & Company MN now owns 148,887 shares of the biotechnology company’s stock worth $1,012,000 after acquiring an additional 47,266 shares during the period. Finally, Bain Capital Public Equity Management LLC grew its holdings in Immune Design Corp. by 393.1% during the second quarter. Bain Capital Public Equity Management LLC now owns 389,400 shares of the biotechnology company’s stock worth $3,797,000 after acquiring an additional 310,433 shares during the period. Institutional investors own 51.46% of the company’s stock.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.